Compare OZ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | ACIU |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | OZ | ACIU |
|---|---|---|
| Price | $50.28 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.9K | ★ 316.4K |
| Earning Date | 03-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,217,000.00 | $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $495.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 244.98 | N/A |
| 52 Week Low | $49.58 | $1.43 |
| 52 Week High | $82.89 | $4.00 |
| Indicator | OZ | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 41.95 |
| Support Level | $49.87 | $2.95 |
| Resistance Level | $51.56 | $3.19 |
| Average True Range (ATR) | 0.68 | 0.22 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 20.71 | 14.71 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.